Arcus Biosciences (RCUS) Total Debt (2024 - 2026)

Arcus Biosciences' Total Debt history runs 3 years deep, the most recent figure standing at $100.0 million for Q1 2026.

• On a quarterly basis, Total Debt rose 108.33% year-over-year to $100.0 million in Q1 2026; TTM through Mar 2026 was $100.0 million, a 108.33% increase from a year earlier, with the FY2025 full-year figure at $99.0 million, up 106.25% from the prior year.
• Total Debt grew to $100.0 million in Q1 2026 per RCUS's latest filing, from $99.0 million in the prior quarter.
• Across five years, Total Debt topped out at $100.0 million in Q1 2026 and bottomed at $47.0 million in Q3 2024.
• The 3-year median for Total Debt is $97.0 million (2025), against an average of $76.7 million.
• Biggest YoY gain for Total Debt was 108.51% in 2025; the steepest drop was 106.25% in 2025.
• Year by year, Total Debt stood at $48.0 million in 2024, then soared by 106.25% to $99.0 million in 2025, then increased by 1.01% to $100.0 million in 2026.
• Per Business Quant, the three latest RCUS Total Debt figures stand at $100.0 million (Q1 2026), $99.0 million (Q4 2025), and $98.0 million (Q3 2025).